Attached files
| file | filename |
|---|---|
| EX-3.1 - COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 201 - ORAMED PHARMACEUTICALS INC. | f10k2020ex3-1_oramedpharma.htm |
| EX-4.4 - DESCRIPTION OF SECURITIES - ORAMED PHARMACEUTICALS INC. | f10k2020ex4-4_oramedpharma.htm |
| 10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC. | f10k2020_oramedpharma.htm |
| EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2020ex32-1_oramedpharma.htm |
| EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2020ex31-2_oramedpharma.htm |
| EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2020ex31-1_oramedpharma.htm |
| EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. - ORAMED PHARMACEUTICALS INC. | f10k2020ex23-1_oramedpharma.htm |
| EX-3.2 - COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 201 - ORAMED PHARMACEUTICALS INC. | f10k2020ex3-2_oramedpharma.htm |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2020, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Avraham Gabay, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: November 24, 2020 | /s/ Avraham Gabay |
| Avraham Gabay | |
| Chief Financial Officer |